p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 2, 2003, Pages 763-772

  Yang, Hui Ling ^a   Pan, Jing Xuan ^a   Sun, Lily ^a   Jim Yeung, Sai Ching ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; COMPLEMENTARY DNA; MANUMYCIN; MESSENGER RNA; METALLOTHIONEIN; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P21;

ALLELE; ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; THYROID CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 3; CASPASES; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; GENE EXPRESSION; HUMANS; MUTAGENESIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; POLYENES; POLYUNSATURATED ALKAMIDES; THYROID NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; ZINC;

EID: 0037328570     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020992     Document Type: Article

References (61)

1. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon 3rd HR 1998 Prospective multicenter study of treatment of thyroid carcinoma: Initial analysis of staging and outcome. Cancer 83:1012-1021
2. Ain K 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715-726
3. Sherman SI 2000 Anaplastic carcinoma: clinical aspects. In: Wartofsky L, ed. Thyroid cancer: a comprehensive guide to clinical management. Totowa, NJ: Humana Press Inc.; 319-325
4. Giuffrida D, Gharib H 2000 Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 11:1083-1089
5. Sweeney PJ, Haraf DJ, Recant W, Kaplan EL, Vokes EE 1996 Anaplastic carcinoma of the thyroid. Ann Oncol 7:739-744
6. Oka Y, Kobayashi T, Fujita S, Matsuura N, Okamoto S, Asakawa H, Murata A, Mori T 1993 Establishment of a human anaplastic thyroid cancer cell line secreting granulocyte colony-stimulating factor in response to cytokines. In Vitro Cell Dev Biol Anim 29A:537-542
7. Palyi I, Peter I, Daubner D, Vincze B, Lorincz I 1993 Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101). Virchows Arch B Cell Pathol Incl Mol Pathol 63:263-269
8. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184
9. La Perle KM, Jhiang SM, Capen CC 2000 Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157:671-677
10. Gotz C, Montenarh M 1996 p53: DNA damage, DNA repair, and apoptosis. Rev Physiol Biochem Pharmacol 127:65-95
11. Lumachi F, Basso S 2002 Apoptosis: life through planned cellular death regulating mechanisms, control systems, and relations with thyroid diseases. Thyroid 12:27-34
12. Yvon AM, Wadsworth P, Jordan MA 1999 Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10:947-959
13. Amos LA, Lowe J 1999 How Taxol stabilises microtubule structure. Chem Biol 6:R65-R69
14. Rowinsky EK 1997 The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48:353-374
15. Ain KB, Tofiq S, Taylor KD 1996 Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81:3650-3653
16. Ain KB, Egorin MJ, DeSimone PA 2000 Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587-594
17. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N 1998 Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 95:1369-1374
18. Nielsen LL, Gurnani M, Shi B, Terracina G, Johnson RC, Carroll J, Mathis JM, Hajian G 2000 Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics. Cancer Res 60:7066-7074
19. Shi B, Yaremko B, Hajian G, Terracina G, Bishop WR, Liu M, Nielsen LL 2000 The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 46:387-393
20. Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, Wood D, Uh M, Tamanoi F 1993 Identification of Ras farnesyltransferase irdhibitors by microbial screening. Proc Natl Acad Sci USA 90:2281-2285
21. Yang W, Del Villar K, Urano J, Mitsuzawa H, Tamanoi F 1997 Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase. J Cell Biochem Suppl 27:12-19
22. Wang W, Macaulay RJ 1999 Apoptosis of medulloblastoma cells in vitro follows inhibition of farnesylation using manumycin A. Int J Cancer 82:30-434
23. Hara M, Han M 1995 Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. Proc Natl Acad Sci USA 92:3333-3337
24. Ito T, Kawata S, Tamura S, Igura T, Nagase T, Miyagawa JI, Yamazaki E, Ishiguro H, Matasuzawa Y 1996 Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Jpn J Cancer Res 87:113-116
25. Yeung SC, Xu G, Pan J, Christgen M, Bamiagis A 2000 Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 60:650-656
26. Xu G, Pan J, Martin C, Yeung SC 2001 Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86:1769-1777
27. Pan J, Xu G, Bamiagis AE, Yeung SC 2001 Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells reduced by manumycin and paclitaxel. J Clin Endocrinol Metab 86:4731-4740
28. Gu WZ, Tahir SK, Wang YC, Zhang HC, Cherian SP, O'Connor S, Leal JA, Rosenberg SH, Ng SC 1999 Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Euro J Cancer 35:1394-1401
29. White FC, Benehacene A, Scheele JS, Kamps M 1997 VEGF mRNA is stabilized by ras and tyrosine kinase oncogenes, as well as by UV radiation: evidence for divergent stabilization pathways. Growth Factors 14:199-212
30. Feldkamp MM, Lau N, Rak J, Kerbel RS, Guha A 1999 Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer 81:118-124
31. Feldkamp MM, Lau N, Guha A 1999 Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogeruc effects. Oncogene 18:7514-7526
32. Charvat S, Duchesne M, Parvaz P, Chignol MC, Schmitt D, Serres M 1999 The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor. Anticancer Res 19:557-561
33. Lerner EC, Hamilton AD, Sebti SM 1997 Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design. Anticancer Drug Des 12:29-238
34. Lobell RB, Kohl NE 1998 Pre-clinical development of farnesyltransferase inhibitors. Cancer Metastasis Rev 17:203-210
35. Du W, Prendergast GC 1999 Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 59:5492-5496
36. Liu A, Du W, Liu JP, Jessell TM, Prendergast GC 2000 RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 20:6105-6113
37. Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ 2000 The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 20:139-148
38. Sepp-Lorenzino L, Rosen N 1998 A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild-type tumor cells. J Biol Chem 273:20243-20251
39. Bissonnette N, Hunting DJ 1998 p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 16:3461-3469
40. Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB, Grant S 2001 Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int J Oncol 19:181-191
41. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S 1999 Apoptosis inhibitory activity of cytoplasmic p21 (Cip1/WAF1) in monocytic differentiation. EMBO J 18:1223-1234
42. Gorospe M, Wang X, Guyton KZ, Holbrook NJ 1996 Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. Mol Cell Biol 16:6654-6660
43. Hsu SL, Chen MC, Chou YH, Hwang GY, Yin SC 1999 Induction o f p21 (CIP1/Waf1) and activation of p34(cdc2) involved in retinoic acid-induced apoptosis in human hepatoma Hep3B cells. Exp Cell Res 248:87-96
44. Avramis VI, Nandy P, Kwock R, Solorzano MM, Mukherjee SK, Danenberg P, Cohen LJ 1998 Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Anticancer Res 18:2327-2338
45. Tsao YP, Huang SJ, Chang JL, Hsieh JT, Pong RC, Chen SL 1999 Adenovirus-mediated p21((WAF1/SDII/CIP1)) gene transfer induces apoptosis of human cervical cancer cell lines. J Virol 73:4983-4990
46. Waldman T, Kinzler KW, Vogelstein B 1995 p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55:5187-5190
47. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B 1993 WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
48. Ramsby ML, Makowski GS 1999 Differential detergent fractionation of eukaryotic cells. In: Link AJ, ed. 2-D proteome analysis protocols. Totowa, NJ: Humana Press; 53-66
49. Lang D, Miknyoczki SJ, Huang L, Ruggeri BA 1998 Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells. Oncogene 16:1593-1602
50. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR 2000 The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 60:5390-5394
51. Shiohara M, el-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP 1994 Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781-3784
52. Ariazi EA, Satomi Y, Ellis MJ, Haag JD, Shi W, Sattler CA, Gould MN 1999 Activation of the transforming growth factor β signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 59:1917-1928
53. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B 1999 Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 96:14517-14522
54. Jeffrey IW, Bushell M, Tilleray VJ, Morley S, Clemens MJ 2002 Inhibition of protein synthesis in apoptosis: differential requirements by the tumor necrosis factor α family and a DNA-damaging agent for caspases and the double-stranded RNA-dependent protein kinase. Cancer Res 62:2272-2280
55. Gervais JL, Seth P, Zhang H 1998 Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis. J Biol Chem 273:19207-19212
56. Park JA, Kim KW, Kim SI, Lee SK 1998 Caspase 3 specifically cleaves p21WAF1/CIP1 in the earlier stage of apoptosis in SK-HEP-1 human hepatoma cells. Eur J Biochem 257:242-248
57. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B 1998 Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501
58. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B 1996 Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10:1945-1952
59. Bellido T, O'Brien CA, Roberson PK, Manolagas SC 1998 Transcriptional activation of the p21(WAF1, CIP1, SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem 273:21137-21144
60. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ 1997 p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 14:929-935
61. Makri D, Schulz WA, Grimm M, Clasen S, Bojar H, Schmitz-Drager BJ 1998 WAF1/p21 regulates proliferation, but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines. Int J Oncol 12:621-628